Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The rise of GLP-1 medications is just one example of a broader trend toward nutritious foods
The Tirzepatide segment is expected to grow at the fastest CAGR in the coming years, driven by a dual GIP and GLP-1 receptor mechanism providing better results for weight loss
Scand J Clin Lab Invest 234(suppl):7585 Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Saxenda (liraglutide) Saxenda is a GLP-1 medication appropriate for adults who: Have obesity (BMI of 30 or above) Have overweight (BMI of 27 or above) along with a weight-related comorbid condition like high blood pressure, type 2 diabetes, or high cholesterol or triglycerides It is also approved for children ages 12 and above who weigh more than 132 pounds and are considered obese
